133258-52-3

Upstream product

• 114433-94-2 1-(4-Fluorophenyl)-3-isopropylpropan-1,3-dione 
• 615-21-4 1,3-benzothiazol-2-ylhydrazine 

Downstream Products

• 133258-57-8 trans-7-[1-(2-Benzothiazolyl)-5-(4-fluorophenyl)-3-(1-methylethyl)-1H-pyrazol-4-yl]-5-hydroxy-3-oxo-6-heptenoic acid, ethyl ester 
• 133258-54-5 (E)-3-[1-Benzothiazol-2-yl-5-(4-fluoro-phenyl)-3-isopropyl-1H-pyrazol-4-yl]-acrylic acid ethyl ester 
• 133258-55-6 (E)-3-[1-Benzothiazol-2-yl-5-(4-fluoro-phenyl)-3-isopropyl-1H-pyrazol-4-yl]-prop-2-en-1-ol 
• 133258-56-7 trans-3-[1-(2-Benzothiazolyl)-5-(4-fluorophenyl)-3-(1-methylethyl)-1H-pyrazol-4-yl]-2-propenal 
• 133258-53-4 2-[4-Bromo-5-(4-fluorophenyl)-3-(1-methylethyl)-1H-pyrazol-1-yl]benzothiazole 

Relevant academic research and scientific papers

Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5- disubstituted-pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones

A series of N-heteroaryl-substituted mevalonolactones were prepared and evaluated for their ability to inhibit the enzyme HMG-CoA reductase both in vitro and in vivo, and to lower plasma cholesterol in a hypercholesterolemic dog model. The goal of the str